Dublin, July 11, 2018 (GLOBE NEWSWIRE) -- The "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.
This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.
The report profiles 27 companies including many key and niche players such as:
- Alcobra Ltd. (Israel)
- Amarantus Bioscience Holdings, Inc. (US)
- Amedra Pharmaceuticals LLC (US)
- Curemark, LLC. (US)
- Eli Lilly and Company (US)
- Intellipharmaceutics International, Inc. (US)
- Janssen Global Services, LLC (US)
- Mallinckrodt PLC (Ireland)
- Mylan N.V. (The Netherlands)
- Neos Therapeutics, Inc. (US)
- Neurovance, Inc. (US)
- Noven Pharmaceuticals, Inc. (US)
- Pfizer Inc. (US)
- Shire plc (Ireland)
- Supernus Pharmaceuticals, Inc. (US)
- Tris Pharma, Inc. (US)
Key Topics Covered
1. MARKET OVERVIEW
ADHD Therapeutics: A Primer
ADHD Therapeutics Market Outlook
Factors Driving ADHD Therapeutics Market
Changes in Insurance Coverage
Addition of Formal Guidelines
Low Diagnosis Threshold
Advancements in Field of Medicine
Unmet Needs
Launch of Pipeline Drugs
Factors Inhibiting ADHD Therapeutics Market
Side Effects Related to Use of Stimulants to Treat ADHD
Under-diagnosis of ADHD Condition
Reduced Availability of Non-Stimulants in Certain Geographies
Competitive Landscape
Major ADHD Medications Available in the Market
ADHD Medications Approved by FDA
Patent Validity for Major ADHD Drugs
2. NOTEWORTHY TRENDS IN ADHD THERAPEUTICS MARKET
Biological Psychiatry Gaining Ground
Social Media Drives Heightened Awareness
Stimulants Dominate the Market but Non-Stimulants Inching Their Way to Popularity
Robust Growth in Pediatric ADHD Therapeutic Market to Propel Overall Market
Strategic Alliances
3. DEVELOPMENTAL PIPELINE OF ADHD DRUGS
An Overview
ADHD Drugs under Phase II/III Development in (2015)
4. ADHD - AN INSIGHT
5. CLINICAL TRIALS
Supernus Announces Positive Results from Phase IIB Trials for SPN-812
Sunovion Announces Top-line Results from Phase II/III Clinical Trial
Taisho Conducts Phase II Trial for TS-141
Shire Announces Positive Top-Line Result from Phase III Trial of SHP465-305
Highland Therapeutics Initiates Phase II Trial for HLD100
FDA Advises Hold for Alcobra Phase III Trial MDX for ADHD
6. PRODUCTS INNOVATIONS/INTRODUCTIONS
Mylan Rolls Out Dextroamphetamine Sulphate Extended Release Capsules
Tris Pharma Introduces Liquid DYANAVEL XR for ADHD
Neos Introduces Adzenys XR-ODT
Shire Introduces Intuniv, Non-Stimulant Treatment for ADHD
Shire Introduces Elvanse Adult, Stimulant Treatment for Adult ADHD
Teva Adds Generic Intuniv to Existing Line of ADHD Products
FDA Approves Pfizer's QuilliChew ER Chewable Tablets
Actavis Introduces Generic Version of Intuniv
7. RECENT INDUSTRY ACTIVITY
Shire Files New Drug Application for Chewable Vyvanse
Medgenics Acquires neuroFix Therapeutics
8. FOCUS ON SELECT GLOBAL PLAYERS
Alcobra Ltd. (Israel)
Amarantus Bioscience Holdings, Inc. (US)
Amedra Pharmaceuticals LLC (US)
Curemark, LLC. (US)
Eli Lilly and Company (US)
Intellipharmaceutics International, Inc. (US)
Janssen Global Services, LLC (US)
Mallinckrodt PLC (Ireland)
Mylan N.V. (The Netherlands)
Neos Therapeutics, Inc. (US)
Neurovance, Inc. (US)
Noven Pharmaceuticals, Inc. (US)
Pfizer Inc. (US)
Shire plc (Ireland)
Supernus Pharmaceuticals, Inc. (US)
Tris Pharma, Inc. (US)
9. GLOBAL MARKET PERSPECTIVE
Total Companies Profiled: 27 (including Divisions/Subsidiaries 28)
- The United States (17)
- Canada (2)
- Japan (2)
- Europe (5)
- The United Kingdom (1)
- Rest of Europe (4)
- Middle East (2)
For more information about this report visit https://www.researchandmarkets.com/research/p2f5b5/global_attention?w=12